14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $1.95 $2.61 Wednesday, 24th Apr 2024 CHRS stock ended at $2.02. This is 7.34% less than the trading day before Tuesday, 23rd Apr 2024. During the day the stock fluctuated 9.41% from a day low at $2.02 to a day high of $2.21.
90 days $1.93 $2.87
52 weeks $1.44 $8.22

Historical Coherus BioSciences prices

Date Open High Low Close Volume
Aug 14, 2023 $4.67 $4.67 $4.42 $4.53 1 778 800
Aug 11, 2023 $4.68 $4.80 $4.67 $4.68 852 637
Aug 10, 2023 $4.61 $4.88 $4.59 $4.75 1 278 897
Aug 09, 2023 $4.85 $4.88 $4.56 $4.59 1 656 802
Aug 08, 2023 $5.02 $5.02 $4.68 $4.79 2 155 411
Aug 07, 2023 $5.05 $5.11 $4.82 $5.02 2 798 526
Aug 04, 2023 $5.15 $5.22 $4.94 $5.07 2 909 658
Aug 03, 2023 $4.75 $5.25 $4.56 $5.11 7 349 031
Aug 02, 2023 $4.42 $4.57 $4.25 $4.34 4 840 432
Aug 01, 2023 $4.84 $4.84 $4.44 $4.49 3 441 651
Jul 31, 2023 $4.91 $4.93 $4.60 $4.82 2 904 617
Jul 28, 2023 $4.64 $4.83 $4.61 $4.79 2 531 371
Jul 27, 2023 $4.60 $4.73 $4.53 $4.60 2 551 808
Jul 26, 2023 $4.44 $4.54 $4.31 $4.53 1 359 884
Jul 25, 2023 $4.40 $4.64 $4.36 $4.42 1 804 221
Jul 24, 2023 $4.51 $4.74 $4.39 $4.40 2 506 745
Jul 21, 2023 $4.19 $4.40 $4.12 $4.29 1 543 951
Jul 20, 2023 $4.39 $4.53 $4.17 $4.17 1 437 650
Jul 19, 2023 $4.42 $4.50 $4.26 $4.38 2 093 513
Jul 18, 2023 $4.44 $4.69 $4.36 $4.39 1 578 054
Jul 17, 2023 $4.10 $4.60 $4.07 $4.37 2 163 164
Jul 14, 2023 $4.33 $4.34 $4.00 $4.06 4 911 475
Jul 13, 2023 $4.51 $4.51 $4.25 $4.27 3 550 890
Jul 12, 2023 $4.79 $4.80 $4.46 $4.47 3 173 341
Jul 11, 2023 $5.20 $5.24 $4.66 $4.69 3 615 140
Click to get the best stock tips daily for free!

About Coherus BioSciences

Coherus BioSciences Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma ... CHRS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT